Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma

Bone Marrow Transplantation volume 31, pages 679–685 (2003)Cite this article

Summary:

Treatment of primary central nervous system lymphoma (PCNSL) with combined high-dose methotrexate (HD-MTX)-based chemotherapy and whole-brain radiotherapy (WBRT) is associated with severe neurotoxicity, but high relapse rates are associated with the use of either modality alone. In an attempt to improve upon these dismal results, we treated seven PCNSL patients with HD-MTX-based induction therapy followed by thiotepa, busulfan, cyclophosphamide (TBC), and autologous stem cell transplant (ASCT), without WBRT. Six of these patients had at least one of the following poor prognostic features: Karnofsky performance status (KPS) ⩽50%, age >60 years, or relapsed disease. All but one patient tolerated the treatment well and experienced improvements in neurological function and overall performance status post-transplant. No treatment-induced neurotoxicity (dementia, ataxia, and incontinence) was observed although the follow-up is short. One early treatment-related death occurred in a patient with multiple comorbid medical conditions. The other six patients achieved a complete response (CR) after TBC and ASCT. Five patients are currently alive and relapse-free at 5, 8, 24, 36, and 42 months from diagnosis. One additional patient relapsed and died 33 months after diagnosis. Two of the seven patients received TBC/ASCT as the only treatment after disease progression following their initial chemotherapy and both remain relapse-free at the time of this report, 22 and 31 months post-TBC/ASCT. In conclusion, prolonged CR can be attained after chemotherapy-only treatment of poor prognosis PCNSL. Furthermore, this small series suggests that high-dose chemotherapy for PCNSL should include drugs that penetrate the CNS such as busulfan and thiotepa rather than standard lymphoma regimens such as BEAM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Benjamin WC, Marcus SM, Topham A et al. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 1997; 79: 2409–2413.

    Article  Google Scholar 

  2. Ferreri AJ, Reni M, Villa E . Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000; 11: 927–937.

    Article  CAS  Google Scholar 

  3. Cher L, Glass J, Harsh GR et al. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996; 46: 1757–1759.

    Article  CAS  Google Scholar 

  4. Mead GM, Bleehen NM, Gregor A et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma. Cancer 2000; 89: 1359–1369.

    Article  CAS  Google Scholar 

  5. Abrey LE, DeAngelis LM, Yahalom J . Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859–863.

    Article  CAS  Google Scholar 

  6. Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin's lymphoma of the brain: can high-dose, large-volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9–17.

    Article  CAS  Google Scholar 

  7. Laperriere NJ, Crerzo L, Milosevic MF et al. Primary lymphoma of brain: results of magagement of a modern cohort with radiation therapy. Radiother Oncol 1997; 43: 247–252.

    Article  CAS  Google Scholar 

  8. DeAngelis LM, Yahalom J, Thaler HT et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10: 635–643.

    Article  CAS  Google Scholar 

  9. Schultz C, Scott C, Sherman W et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group protocol 88-06. J Clin Oncol 1996; 14: 556–564.

    Article  CAS  Google Scholar 

  10. Abrey LE, Yahalom J, DeAngelis LM . Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 17: 3144–3150.

    Article  Google Scholar 

  11. Guha-Thakurta N, Damek D, Pollack C et al. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999; 43: 259–268.

    Article  CAS  Google Scholar 

  12. Bessell EM, Lopez-Guillermo A, Villa S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by tow different radiotherapy treatments. J Clin Oncol 2002; 20: 231–236.

    Article  CAS  Google Scholar 

  13. Soussain C, Merle-Beral H, Reux I et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma 1996; 23: 339–345.

    Article  CAS  Google Scholar 

  14. Soussain C, Suzan F, Hoang-Xuan K et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742–749.

    Article  CAS  Google Scholar 

  15. van Besien K, Przepiorka D, Mehra R et al. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol 1996; 14: 3036–3042.

    Article  CAS  Google Scholar 

  16. Gopal AK, Gooley TA, Golden JB et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593–599.

    Article  CAS  Google Scholar 

  17. Glass J, Gruber ML, Cher L et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81: 188–195.

    Article  CAS  Google Scholar 

  18. Blay J, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary CNS lymphoma: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864–871.

    Article  CAS  Google Scholar 

  19. Ervin T, Canellos GP . Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 1980; 45: 1556–1557.

    Article  CAS  Google Scholar 

  20. Frick JC, Hansen RM, Anderson T, Ritch PS . Successful high-dose intravenous cytarabine treatment of parenchymal involvement from malignant lymphoma. Arch Intern Med 1986; 146: 791–792.

    Article  CAS  Google Scholar 

  21. Hassan M, Ehrsson H, Smedmyr B et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant 1989; 4: 113–114.

    CAS  Google Scholar 

  22. Wiebe VJ, Smith BR, DeGregorio MW, et al: Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol/Hematol 1992; 13: 241–270.

    Article  CAS  Google Scholar 

  23. Heideman RL, Cole DE, Balis F et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736–741.

    CAS  Google Scholar 

  24. van Besien K, Forman A, Champlin R . Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol 1997; 8: 515–524.

    Article  CAS  Google Scholar 

  25. Khalfallah S, Stamatoullas A, Fruchart C et al. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1021–1023.

    CAS  PubMed  Google Scholar 

  26. Marks R, Warnke P, Guttenberger R et al. Primary CNS lymphoma (PCNSL): high-dose chemotherapy with autologous PBSCT and hyperfractionated radiotherapy within first-line treatment. Ann Oncol 1999; 10: (Suppl 3): 15 (Abstr. 42).

    Google Scholar 

  27. Abrey LE, Moskowitz CH, Mason WP et al. A phase II study of intensive methotrexate and cytarabine followed by high dose BEAM chemotherapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL). Proc ASCO 2001; 20: 53a (Abstr. 207).

    Google Scholar 

  28. DeAngelis LM, Yahalom J . Primary central nervous system lymphoma. In: DeVita VT (ed). Cancer: Principles & Practice of Oncology, 6th edn. Lippincott Williams & Wilkins: Philadelphia, 2001, pp 2330–2339.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Tom Baker Cancer Centre, University of Calgary, Calgary, Alta., Canada

    T Cheng, A Chaudhry, D Morris, S Glück, J A Russell & D A Stewart

  2. Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alta., Canada

    T Cheng, P Forsyth, A Chaudhry, D Morris, S Glück, J A Russell & D A Stewart

  3. Department of Clinical Neurosciences, Tom Baker Cancer Centre, University of Calgary, Calgary, Alta., Canada

    P Forsyth

Authors
  1. T Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Forsyth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Chaudhry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Glück
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J A Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D A Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheng, T., Forsyth, P., Chaudhry, A. et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31, 679–685 (2003). https://doi.org/10.1038/sj.bmt.1703917

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703917

Keywords

This article is cited by

Search

Advanced search

Quick links